Shopping Cart

Your shopping cart is currently empty

Mitotane

Name: Mitotane
Brand: TargetMol
SKU: T1199
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1199Cas No. 53-19-0

Alias o,p'-DDD, NCI-C04933, Mitotan, 2,4′-DDD

Mitotane (NCI-C04933) is a derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Mitotane

Copy Product Info

🥰Excellent

Purity: 99.96%

Catalog No. T1199Alias o,p'-DDD, NCI-C04933, Mitotan, 2,4′-DDDCas No. 53-19-0

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$30	In Stock	In Stock
100 mg	$40	In Stock	In Stock
500 mg	$88	In Stock	In Stock
1 g	$128	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$39	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.96%

Appearance:Solid

Color:White

Resource Download

COA HPLC HNMR

Product Introduction

Mitotane AI Summary

Mitotane displays a high octanol-water partition coefficient with a log P value of 6.0, indicating significant lipophilicity and likely high membrane permeability. The compound exhibits a diverse range of bioactivities, presenting potency in numerous assays targeting various biological pathways. These include modulation of Lamin A splicing, JMJD2E inhibition, hypoxia response induction, mitochondrial division and fusion modulation, thyroid stimulating hormone receptor activation, TDP1 inhibition, mitochondrial channel activity inhibition, retinoid X receptor alpha signaling activation, inhibition of DNA re-replication, and inhibition of tumor cell line growth, indicating extensive pharmacological potential. It also binds to and modulates several receptors and transporters, including adenosine A3, alpha-2A adrenergic, and various serotonin receptors and transporters, with moderate to high affinity (IC50/Ki values in the nM range). Despite this extensive bioactivity, Mitotane shows no induction of drug-induced liver injury, as indicated by a DILIps prediction score of 0.0 for various hepatic conditions, though some reports suggest moderate liver toxicity. Further, it shows inhibitory activity against human BSEP and OATP1B1 and OATP1B3 transfected CHO cells. Its hepatobiliary transporter interactions suggest significant effects on bile acid and drug transport. Additionally, it has demonstrated antiviral activity against SARS-CoV-2, albeit with variable efficacy. The compound is an inhibitor of human HDAC6, showing mild inhibition in enzymatic assays. It also induces CYP3A4, significantly reducing midazolam AUC by 94%, which highlights its role in drug metabolism. In receptor binding assays, it displays affinity towards multiple receptors (e.g., NR3C1, CNR1, AR, NR1I2, PGR), suggesting agonist or antagonist activity depending on the context. Collectively, Mitotane stands out due to its wide spectrum of bioactivity, high lipophilicity, selective receptor interactions, antiviral potential, and specific enzymatic inhibition, with varied implications for pharmacological development and therapeutic application..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Mitotane (NCI-C04933) is a derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
In vitro	10-40 μM Mitotane inhibited basal and cAMP-induced cortisol secretion but did not cause cell death.Mitotane inhibited basal expression of StAR and P450scc proteins.40 μM Mitotane significantly reduced mRNA expression of StAR, CYP11A1 and CYP21.In H295R cells, the mRNA expression of StAR, CYP11A1 and CYP21 was significantly reduced by Mitotane. In H295R cells, Mitotane in combination with gemcitabine showed antagonistic effects and interfered with gemcitabine-mediated S-phase inhibition of the cell cycle.Mitotane inhibited the expression and secretion of thyroid stimulating hormone (TSH), blocked TSH response to thyrotropin-releasing hormone (THRH), decreased cell viability, and induced apoptosis in the mouse TalphaT1 cell line.Mitotane inhibited the expression and secretion of pituitary thyrotropin secretory hormone (PTHS) and induced apoptosis in the pituitary thyrotropin secretory hormone (PSH) cells. Mitotane induced adrenocortical necrosis, mitochondrial membrane damage, and irreversible binding of the protein CYP in pituitary thyrotropin-secreting mouse cells, without interfering with thyroid hormones, and directly reduced secretory activity and cell viability.
In vivo	10-40 μM Mitotane inhibited basal and cAMP-induced cortisol secretion but did not cause cell death.Mitotane inhibited basal expression of StAR and P450scc proteins.40 μM Mitotane significantly reduced mRNA expression of StAR, CYP11A1 and CYP21.In H295R cells, the mRNA expression of StAR, CYP11A1 and CYP21 was significantly reduced by Mitotane. In H295R cells, Mitotane in combination with gemcitabine showed antagonistic effects and interfered with gemcitabine-mediated S-phase inhibition of the cell cycle.Mitotane inhibited the expression and secretion of thyroid stimulating hormone (TSH), blocked TSH response to thyrotropin-releasing hormone (THRH), decreased cell viability, and induced apoptosis in the mouse TalphaT1 cell line.Mitotane inhibited the expression and secretion of pituitary thyrotropin secretory hormone (PTHS) and induced apoptosis in the pituitary thyrotropin secretory hormone (PSH) cells. Mitotane induced adrenocortical necrosis, mitochondrial membrane damage, and irreversible binding of the protein CYP in pituitary thyrotropin-secreting mouse cells, without interfering with thyroid hormones, and directly reduced secretory activity and cell viability.
Synonyms	o,p'-DDD, NCI-C04933, Mitotan, 2,4′-DDD

Chemical Properties

Molecular Weight	320.04
Formula	C₁₄H₁₀Cl₄
Cas No.	53-19-0
Smiles	ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl
Relative Density.	1.372 g/cm3

Storage & Solubility Information

Storage

store under nitrogen | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 250 mg/mL (781.15 mM), Sonication is recommended.

Ethanol: 60 mg/mL (187.48 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.25 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	3.1246 mL	15.6230 mL	31.2461 mL	156.2305 mL
5 mM	0.6249 mL	3.1246 mL	6.2492 mL	31.2461 mL
10 mM	0.3125 mL	1.5623 mL	3.1246 mL	15.6230 mL
20 mM	0.1562 mL	0.7812 mL	1.5623 mL	7.8115 mL
50 mM	0.0625 mL	0.3125 mL	0.6249 mL	3.1246 mL
100 mM	0.0312 mL	0.1562 mL	0.3125 mL	1.5623 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc